CASP3 and chronic kidney disease: Figure 8C,D shows that the Bax/Bcl-2 expression ratio and the Casp3 expression level in adenine-induced CKD mice were significantly higher at 1.42- and 1.95-fold (p < 0.001), respectively, than those in control mice. HY7718 treatment significantly reduced these parameters to 0.93- (p < 0.001) and 1.51-fold (p < 0.05), respectively. In APN-treated mice, the Bax/Bcl-2 ratio and expression level of Casp3 were reduced to 1.29- and 1.77-fold, respectively.